Revvity Inc. (NYSE:RVTY) Stock Has Consensus Price Target of $136.71 According to Brokerages

Revvity logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is mostly neutral: 19 analysts give Revvity a consensus “Hold” rating, with an average 12-month price target of $136.71. Recent targets range from $172 at RBC to $200 at KeyCorp.
  • Quarterly results topped expectations: Revvity reported adjusted earnings of $1.38 per share versus $1.30 expected, and revenue of $728.9 million versus $694.7 million expected; revenue grew 4.3% year over year.
  • Insiders have been selling shares: Company insiders sold 9,045 shares worth about $1.28 million over the last quarter, while institutional investors own 86.65% of the stock.
  • Five stocks to consider instead of Revvity.

Revvity Inc. (NYSE:RVTY - Get Free Report) has been assigned an average rating of "Hold" from the nineteen analysts that are covering the company, MarketBeat Ratings reports. Thirteen research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $136.71.

Several equities research analysts have recently issued reports on RVTY shares. KeyCorp restated an "overweight" rating and set a $200.00 price target on shares of Revvity in a research note on Monday. Bank of America restated a "neutral" rating on shares of Revvity in a research report on Wednesday, November 4th. Zacks Research raised Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Royal Bank Of Canada lifted their price objective on Revvity from $135.00 to $172.00 and gave the stock a "sector perform" rating in a report on Wednesday, November 4th. Finally, Barclays lifted their price objective on Revvity from $160.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, November 4th.

View Our Latest Stock Report on Revvity

Insiders Place Their Bets

In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,045 shares of company stock valued at $1,281,439 over the last quarter. 0.85% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jupiter Topco LLC purchased a new stake in shares of Revvity during the 2nd quarter worth approximately $961,017,000. BlackRock Inc. bought a new position in shares of Revvity during the 2nd quarter valued at approximately $852,070,000. Durable Capital Partners LP bought a new position in shares of Revvity during the 3rd quarter valued at approximately $201,890,000. Wellington Management Group LLP boosted its position in shares of Revvity by 10,653.8% during the 2nd quarter. Wellington Management Group LLP now owns 865,575 shares of the company's stock valued at $96,304,000 after acquiring an additional 857,526 shares during the last quarter. Finally, Primecap Management Co. CA purchased a new position in shares of Revvity in the second quarter valued at $94,921,000. Institutional investors own 86.65% of the company's stock.

Revvity Stock Performance

Shares of Revvity stock opened at $145.21 on Friday. The company has a market cap of $16.21 billion, a P/E ratio of 64.25, a PEG ratio of 2.61 and a beta of 1.08. Revvity has a 1-year low of $81.22 and a 1-year high of $171.74. The business has a 50-day moving average price of $152.86 and a two-hundred day moving average price of $115.35. The company has a current ratio of 2.65, a quick ratio of 2.10 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.30 by $0.08. The firm had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The company's quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 earnings per share. As a group, analysts anticipate that Revvity will post 5.42 EPS for the current year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Stockholders of record on Friday, January 22nd will be issued a $0.07 dividend. The ex-dividend date is Friday, January 22nd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity's dividend payout ratio (DPR) is currently 12.39%.

About Revvity

(Get Free Report)

Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company's work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.

Featured Stories

Analyst Recommendations for Revvity (NYSE:RVTY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Revvity Right Now?

Before you consider Revvity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.

While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines